Sipavibart could soon gain European approval for pre-exposure COVID-19 prophylaxis, its marketing application having recently been accepted, but AstraZeneca PLC’s antibody will be a latecomer; several other options are on the market and it is not clear how big this niche is.
Key Takeaways
- The European marketing application for AstraZeneca’s sipavibart, designed to prevent immunocompromised people contracting COVID-19, has been accepted.
- The only antibody currently available for this use is Invivyd’s Pemgarda, and that is only on sale in the US
AstraZeneca’s own Evushield (tixagevimab/cilgavimab) was highly successful in this space, selling more than $2bn in 2022, but its US marketing authorization was rescinded in 2023 when it became clear that Evushield was ineffective against some of the newer variants of
